

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**LUYE PHARMA GROUP LTD.**

**绿叶制药集团有限公司**

*(Incorporated in Bermuda with limited liability)*

(Stock Code: 02186)

**ANNOUNCEMENT  
IN RELATION TO THE 2022 ANNUAL REPORT**

References are made to the annual report (the “**2022 Annual Report**”) of Luye Pharma Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2022 (“**FY2022**”). Capitalised terms used herein shall have the same meanings as those defined in the 2022 Annual Report unless the context requires otherwise.

The Board would like to provide the following further information in relation to the share award scheme adopted by the Company on 10 January 2017 (the “**Share Award Scheme**”). The table below sets out the movements of the share awards granted under the Share Award Scheme during FY2022:

	Date of grant	Number of unvested Awarded Shares as at 1 January 2022	Number of Awarded Shares				Number of unvested Awarded Shares as at 31 December 2022	Vesting period <sup>(1)</sup>	Award price
			Granted during the FY2022	Vested during the FY2022	Cancelled during the FY2022	Lapsed during the FY2022			
Grantees									
638 employees <sup>(2)</sup>	15 May 2019	26,389,000	—	25,206,000	1,183,000	—	—	15 May 2022	HK\$4

Notes:

- The date indicated above are the earliest date that the Awarded Shares may be vested, from which the Awarded Shares may be vested up to the date of termination of the Share Award Scheme. There is no performance target required for the vesting of the Awarded Shares, except the eligible participant remains as an employee of the Group during the vesting period and meet the expectation of the Company on daily performance.

2. Other than these employees, no Directors or other employees of the Group held any unvested Awarded Shares as at 1 January 2022 and 31 December 2022. Among the Awarded Shares held by these employees, 25,206,000 Awarded Shares were vested on 15 May 2022. The unvested Awarded Shares held by the five highest paid employees of the Group for FY2022 were amounted to 1,135,000 in aggregate as at 1 January 2022 and all of such Awarded Shares were also vested on 15 May 2022, following which these five highest paid employees held no unvested Awarded Shares as at 31 December 2022. The closing price of the Shares as quoted on the Stock Exchange's website immediately before the aforementioned vesting date (i.e. 13 May 2022) was HK\$2.33 per Share.

By Order of the Board  
**LUYE PHARMA GROUP LTD.**  
**Liu Dian Bo**  
*Chairman*

Hong Kong, 13 October 2023

*As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. SUN Xin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.*